Adam R. Levy, serving as both Chief Executive Officer and a director at NEXGEL, INC. (NASDAQ:NXGL), completed a transaction involving the disposal of company equity on June 11, 2026. According to the filing, Mr. Levy sold 3,000 shares of the company's common stock through an open market mechanism. The execution price for these shares was recorded at $0.6136 each, generating a total transaction value of $1,840. Following the completion of this sale, Mr. Levy's direct ownership stake in NEXGEL common stock stands at 333,692 shares.
The timing of this insider sale coincides with a difficult valuation period for the company. NEXGEL shares are currently trading at approximately $0.54, a level that reflects substantial pressure on the stock. Data indicates that the equity has suffered a 79% decline over the trailing twelve months and a 66% drop over the preceding six months. Despite these pronounced headwinds, analytical assessments from InvestingPro suggest that the current valuation may present an undervalued position for the stock. Investors interested in further granular data can access six additional InvestingPro Tips, which include specific evaluations of the company's debt load and ongoing cash flow dynamics.
Financial disclosures from Nexgel Inc. for the first quarter of 2026 provide additional context to the operational landscape. The company reported a net loss per share of -0.11 USD for the period. Revenue for the quarter was recorded at 2.65 million USD, marking a 5.7% contraction compared to the same period in the previous year. Despite this revenue decline, management has articulated optimism regarding future growth trajectories, citing the strategic impact of the recent acquisition of BioNX.
Concurrently, Nexgel has advanced its clinical research efforts. The firm announced the outcomes of a clinical study evaluating its hydrogel patch technology. The research, which involved a cohort of 30 patients, demonstrated that the hydrogel patch effectively reduced plume concentration by 95.6% during laser hair removal procedures when compared to a control group. This clinical trial was conducted at the Florida Clinical Research Center and received funding from Innovative Optics. The results of this study were subsequently published in the journal Lasers in Surgery and Medicine, underscoring the company's commitment to clinical validation alongside its strategic business developments.